Abstract
This study investigated the effects of 24-hour intravenous infusion of glutathione (GSH) on plasma malondialdehyde (MDA) levels and on clinical recovery after myocardial infarction in 67 patients treated with recombinant tissue-type plasminogen activator (rt-PA) and 29 patients not given rt-PA. Baseline MDA levels were also measured in 20 healthy control subjects matched for sex, age, and smoking habits. Administration of rt-PA resulted in an earlier recovery of ST elevation. A higher number of patients with fast ST recovery, a lower creatine phosphokinase (CPK) maximum peak, earlier CPK peak, and a lower incidence of arrhythmic episodes were among those who received GSH in addition to rt-PA. Patients who did not receive rt-PA showed a rather steady trend of plasma MDA levels. Patients receiving thrombolytic therapy showed increased MDA concentrations beginning 6 hours after starting therapy. However, while the patients treated only with rt-PA showed a continuous increase in MDA levels, those patients who also received GSH had a significant decrease in MDA levels. Plasma MDA levels significantly increased after thrombolysis; administration of GSH appeared to limit some adverse effects associated with reperfusion-induced oxidative stress.
| Original language | English |
|---|---|
| Pages (from-to) | 131-141 |
| Number of pages | 11 |
| Journal | Current Therapeutic Research |
| Volume | 57 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1996 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
High-dose antioxidant therapy during thrombolysis in patients with acute myocardial infarction. / Altomare, Emanuele; Colonna, Paolo; D'Agostino, Carlo; Castellaneta, Giustina; Vendemiale, Gianluigi; Grattagliano, Ignazio; Cirelli, Francesca; Bovenzi, Francesco; Colonna, Luigi.
In: Current Therapeutic Research, Vol. 57, No. 2, 1996, p. 131-141.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - High-dose antioxidant therapy during thrombolysis in patients with acute myocardial infarction
AU - Altomare, Emanuele
AU - Colonna, Paolo
AU - D'Agostino, Carlo
AU - Castellaneta, Giustina
AU - Vendemiale, Gianluigi
AU - Grattagliano, Ignazio
AU - Cirelli, Francesca
AU - Bovenzi, Francesco
AU - Colonna, Luigi
PY - 1996
Y1 - 1996
N2 - This study investigated the effects of 24-hour intravenous infusion of glutathione (GSH) on plasma malondialdehyde (MDA) levels and on clinical recovery after myocardial infarction in 67 patients treated with recombinant tissue-type plasminogen activator (rt-PA) and 29 patients not given rt-PA. Baseline MDA levels were also measured in 20 healthy control subjects matched for sex, age, and smoking habits. Administration of rt-PA resulted in an earlier recovery of ST elevation. A higher number of patients with fast ST recovery, a lower creatine phosphokinase (CPK) maximum peak, earlier CPK peak, and a lower incidence of arrhythmic episodes were among those who received GSH in addition to rt-PA. Patients who did not receive rt-PA showed a rather steady trend of plasma MDA levels. Patients receiving thrombolytic therapy showed increased MDA concentrations beginning 6 hours after starting therapy. However, while the patients treated only with rt-PA showed a continuous increase in MDA levels, those patients who also received GSH had a significant decrease in MDA levels. Plasma MDA levels significantly increased after thrombolysis; administration of GSH appeared to limit some adverse effects associated with reperfusion-induced oxidative stress.
AB - This study investigated the effects of 24-hour intravenous infusion of glutathione (GSH) on plasma malondialdehyde (MDA) levels and on clinical recovery after myocardial infarction in 67 patients treated with recombinant tissue-type plasminogen activator (rt-PA) and 29 patients not given rt-PA. Baseline MDA levels were also measured in 20 healthy control subjects matched for sex, age, and smoking habits. Administration of rt-PA resulted in an earlier recovery of ST elevation. A higher number of patients with fast ST recovery, a lower creatine phosphokinase (CPK) maximum peak, earlier CPK peak, and a lower incidence of arrhythmic episodes were among those who received GSH in addition to rt-PA. Patients who did not receive rt-PA showed a rather steady trend of plasma MDA levels. Patients receiving thrombolytic therapy showed increased MDA concentrations beginning 6 hours after starting therapy. However, while the patients treated only with rt-PA showed a continuous increase in MDA levels, those patients who also received GSH had a significant decrease in MDA levels. Plasma MDA levels significantly increased after thrombolysis; administration of GSH appeared to limit some adverse effects associated with reperfusion-induced oxidative stress.
UR - http://www.scopus.com/inward/record.url?scp=0029975907&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029975907&partnerID=8YFLogxK
U2 - 10.1016/S0011-393X(96)80007-5
DO - 10.1016/S0011-393X(96)80007-5
M3 - Article
VL - 57
SP - 131
EP - 141
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
SN - 0011-393X
IS - 2
ER -